Jiangsu Nata Opto-electronic Material (300346.SZ) plans to acquire 16.5398% equity of Quanjiao Nanda for 230 million yuan to improve decision-making efficiency.
Nanda Optoelectronics (300346.SZ) announced that the company plans to acquire Suzhou Nansheng Investment No.1 Enterprise Management Partnership Enterprise in cash.
Jiangsu Nata Opto-electronic Material (300346.SZ) announced that it plans to acquire 16.5398% equity of Quanjiao Jiangsu Nata Opto-electronic Material Co., Ltd. (referred to as Quanjiao Nanda) held by Suzhou Nancheng No.1 Enterprise Management Partnership Enterprise (Limited Partnership) (referred to as Nancheng No.1) in cash at a transaction price of RMB 230 million. After the completion of the transaction, Quanjiao Nanda will change from a subsidiary of the company to a wholly-owned subsidiary.
As the main research and production base of phosphine and arsine for the company, the product quality and production capacity of Quanjiao Nanda have reached the international advanced level and have been highly recognized by customers. While expanding the existing product market, Quanjiao Nanda continuously enriches the product matrix and actively develops new generations of safe sources, isotope products, mixed gas products, etc., which are widely used in the fields of chip, memory manufacturing, new energy, and third-generation semiconductors, with broad market prospects. After the completion of the transaction, the company will achieve 100% equity ownership of Quanjiao Nanda, which will help improve decision-making efficiency, better introduce business resources at the group level, strengthen the management and coordination of various business sectors, optimize and strengthen the electronic specialty gas business, and enhance the company's core competitiveness.
Related Articles

Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.

CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.

On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.
Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.

CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.

On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.

RECOMMEND

General Administration of Customs: China's goods trade imports and exports increased by 2.4% year-on-year in the first 4 months.
09/05/2025

Key details are yet to be finalized. The market's response to the US-UK trade agreement has been lukewarm.
09/05/2025

Risk assets rebounded to boost the market, Bitcoin surged back above $100,000.
09/05/2025